Human Flt3L generates dendritic cells from canine peripheral blood precursors: Implications for a dog glioma clinical trial

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Xiong, Weidong ^a   Candolfi, Marianela ^a   Liu, Chunyan ^a   Ghulam Muhammad, A K M ^a   Yagiz, Kader ^a   Puntel, Mariana ^a   Moore, Peter F ^b   Avalos, Julie ^c   Young, John D ^c   Khan, Dorothy ^c   Donelson, Randy ^d   Pluhar, G Elizabeth ^e   Ohlfest, John R ^d,e   Wawrowsky, Kolja ^a   Lowenstein, Pedro R ^a   Castro, Maria G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD14 ANTIGEN; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOG; GENE EXPRESSION; GLIOMA; LEUKOCYTE CULTURE; LYMPHOCYTE CULTURE; MIXED LYMPHOCYTE REACTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS;

ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; DOG DISEASES; DOGS; GENETIC VECTORS; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; IMMUNOTHERAPY; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; PHAGOCYTOSIS;

CANIS FAMILIARIS; HERPES; RODENTIA;

EID: 77956211427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011074     Document Type: Article

References (42)

1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
2. Martin V, Liu D, Gomez-Manzano C (2009) Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des 15: 353-364.
3. Barth RF (2009) Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 67: S3-6.
4. Parker JN, Bauer DF, Cody JJ, Markert JM (2009) Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558-569.
5. Asadi-Moghaddam K, Chiocca EA (2009) Gene- and viral-based therapies for brain tumors. Neurotherapeutics 6: 547-557.
6. Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, et al. (2009) Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther 9: 409-421.
7. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, et al. (2009) Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 15: 4401-4414.
8. Muhammad AKMG, Candolfi M, King GD, Yagiz K, Foulad D, et al. (2009) Antiglioma Immunological Memory in Response to Conditional Cytotoxic/ Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. Clinical Cancer Research 15: 6113-6127.
9. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, et al. (2005) Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65: 7194-7204.
10. Curtin J, Liu N, Candolfi M, Xiong W, Assi A, et al. (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Medicine 6: e10.
11. Curtin JF, King GD, Barcia C, Liu C, Hubert FX, et al. (2006) Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 176: 3566-3577.
12. Heidner GL, Kornegay JN, Page RL, Dodge RK, Thrall DE (1991) Analysis of survival in a retrospective study of 86 dogs with brain tumors. J Vet Intern Med 5: 219-226.
13. Foster ES, Carrillo JM, Patnaik AK (1988) Clinical signs of tumors affecting the rostral cerebrum in 43 dogs. J Vet Intern Med 2: 71-74.
14. LeCouteur RA (1999) Current concepts in the diagnosis and treatment of brain tumours in dogs and cats. J Small Anim Pract 40: 411-416.
15. Stonehewer J, Mackin AJ, Tasker S, Simpson JW, Mayhew IG (2000) Idiopathic phenobarbital-responsive hypersialosis in the dog: an unusual form of limbic epilepsy? J Small Anim Pract 41: 416-421.
16. Stoica G, Kim HT, Hall DG, Coates JR (2004) Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas. Vet Pathol 41: 10-19.
17. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85: 133-148.
18. Lipsitz D, Higgins RJ, Kortz GD, Dickinson PJ, Bollen AW, et al. (2003) Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs. Vet Pathol 40: 659-669.
19. Orrison WW, Jr., Rose DF, Hart BL, Maclin EL, Sanders JA, et al. (1992) Noninvasive preoperative cortical localization by magnetic source imaging. AJNR Am J Neuroradiol 13: 1124-1128.
20. Braund K (2003) Neoplasia of the Nervous System. In: Braund K, ed. Clinical Neurology in Small Animals - Localization, Diagnosis and Treatment. IthacaNew York: International Veterinary Information Service (www.ivis.org). pp B02270203.
21. Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, et al. (2007) Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery 60: 167-177; discussion 178.
22. Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, et al. (2007) Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol 9: 245-258.
23. Oh S, Pluhar GE, McNeil EA, Kroeger KM, Liu C, et al. (2007) Efficacy of nonviral gene transfer in the canine brain. J Neurosurg 107: 136-144.
24. Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, et al. (2006) Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 60: 204-213.
25. Weber M, Lange C, Gunther W, Franz M, Kremmer E, et al. (2003) Minor histocompatibility antigens on canine hemopoietic progenitor cells. J Immunol 170: 5861-5868.
26. Hagglund HG, McSweeney PA, Mathioudakis G, Bruno B, Georges GE, et al. (2000) Ex vivo expansion of canine dendritic cells from CD34+ bone marrow progenitor cells. Transplantation 70: 1437-1442.
27. Mielcarek M, Kucera KA, Nash R, Torok-Storb B, McKenna HJ (2007) Identification and characterization of canine dendritic cells generated in vivo. Biol Blood Marrow Transplant 13: 1286-1293.
28. Ibisch C, Pradal G, Bach JM, Lieubeau B (2005) Functional canine dendritic cells can be generated in vitro from peripheral blood mononuclear cells and contain a cytoplasmic ultrastructural marker. J Immunol Methods 298: 175-182.
29. Wijewardana V, Sugiura K, Oichi T, Fujimoto M, Akazawa T, et al. (2006) Generation of canine dendritic cells from peripheral blood monocytes without using purified cytokines. Vet Immunol Immunopathol 114: 37-48.
30. Bonnefont-Rebeix C, de Carvalho CM, Bernaud J, Chabanne L, Marchal T, et al. (2006) CD86 molecule is a specific marker for canine monocyte-derived dendritic cells. Vet Immunol Immunopathol 109: 167-176.
31. Catchpole B, Stell AJ, Dobson JM (2002) Generation of blood-derived dendritic cells in dogs with oral malignant melanoma. J Comp Pathol 126: 238-241.
32. King GD, Muhammad AKM, Curtin JF, Barcia C, Puntel M, et al. (2008) Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 10: 19-31.
33. Wernette CM, Smith BF, Barksdale ZL, Hecker R, Baker HJ (2002) CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 84: 223-236.
34. Hashimoto M, Asahina Y, Sano J, Kano R, Moritomo T, et al. (2005) Cloning of canine toll-like receptor 9 and its expression in dog tissues. Vet Immunol Immunopathol 106: 159-163.
35. Kurata K, Iwata A, Masuda K, Sakaguchi M, Ohno K, et al. (2004) Identification of CpG oligodeoxynucleotide sequences that induce IFN-gamma production in canine peripheral blood mononuclear cells. Vet Immunol Immunopathol 102: 441-450.
36. House AK, Gregory SP, Catchpole B (2008) Pattern-recognition receptor mRNA expression and function in canine monocyte/macrophages and relevance to canine anal furunuclosis. Vet Immunol Immunopathol 124: 230-240.
37. Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, et al. (2008) Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyteproliferation and cytokine production in vitro. Vet Immunol Immunopathol 124: 120-131.
38. Ali S, Curtin JF, Zirger JM, Xiong W, King GD, et al. (2004) Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 10: 1071-1084.
39. Southgate T, Kroeger KM, Liu C, Lowenstein PR, Castro MG (2008) Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci Chapter 4: Unit 4 23.
40. Nyberg-Hoffman C, Aguilar-Cordova E (1999) Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med 5: 955-957.
41. Dion LD, Fang J, Garver RI, Jr. (1996) Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods 56: 99-107.
42. Cotten M, Baker A, Saltik M, Wagner E, Buschle M (1994) Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther 1: 239-246.